Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).

作者： Katrin Marie Sjoquist , Nick Pavlakis , Andrew James Martin , Eric Tsobanis , Sonia Yip

DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS4136

关键词: Gastro oesophageal cancer 、 Double blind 、 Placebo-controlled study 、 Surgery 、 Refractory 、 Medicine 、 Internal medicine 、 Gastroenterology 、 Standard treatment 、 Poor prognosis 、 Regorafenib 、 Chemotherapy